GlobeNewsWire
21 May 2026, 21:10 UTC · 17w ago
Verdict
Headline takes no side. We score AUTL +0.80 across two claims — strongly bullish.
+0.80strongly bullish
More positive than 86% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish
Obe-cel demonstrated an overall response rate of 59% and a median duration of response of 42.6 months in B-ALL patients with extramedullary disease (EMD).
So whatPositive clinical efficacy in a difficult-to-treat patient population typically associated with poor survival increases the potential market share and valuation of the drug.
More positive than 93% of claims this week
Autolus Therapeutics will present a clinical data update for obe-cel at the ASCO Annual Meeting on May 30, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 64% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company is presenting positive clinical data for obe-cel showing strong response rates in a difficult-to-treat patient population.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
8h ago
+18.2%
Price agrees with the score
$1.95 vs $1.65 close before publication (May 21) · not market-adjusted
AUTL chart →
